Just as a massiveresearch attack on cancer genetics in the 1980s is now paying dividends in terms ofdrug treatment, so the genetic description of key signalling molecules and mediatorsin the pain system has provided many new targets (e.g., P2RX7,SCN9A) for analgesic drugs that are under development. The gene discussed is SCN9A; the disease is cancer.